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Long-acting beta2-
adrenoreceptor agonists: 
salmeterol and formoterol
The long-acting beta2-adrenoreceptor agonists salmeterol and 
formoterol, given by inhalation, have a bronchodilating effect lasting 
for at least 12 hours after a single administration. They complement 
but not substitute inhaled glucocorticoids in the management of 
asthma and are also used in the management of chronic obstructive 
pulmonary disease (COPD).
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Introduction
Inhaled short-acting beta2-
adrenoreceptor agonists have been used for 
over 40 years in the treatment of asthma. 
They are considered as first-line therapy 
for asthma treatment as they provide rapid 
bronchodilation and protect against stimuli, 
such as exercise, allergen, or pollutants 
that cause bronchoconstriction in asthmatic 
patients.1 Salmeterol and formoterol are 
the first two drugs of a new generation of 
long-acting beta2-adrenoreceptor agonists	
given by inhalation with bronchodilating 
effects lasting for at least 12 hours after 
a single administration. Both of these 
drugs have become important complements 
in the regular management of asthmatic 
patients who are not sufficiently controlled 
with inhaled glucocorticoids.2 Also, regular 
use of a long-acting beta2-adrenoreceptor 
agonist improves health status in patients 
with COPD. 
Pharmacological	differences
Formoterol and salmeterol have similar 
pharmacological properties: both are highly 
selective and potent beta2-adrenoreceptor 
agonists, with relaxant effects on bronchial 
smooth muscle in vitro. However, some 
significant pharmacological differences 
between these drugs have been documented 
in vitro and in patients, as shown in 
Table 1.2
Formoterol has a more rapid onset of 
action than salmeterol, which may make 
formoterol suitable for symptom relief 
as well as symptom prevention in the 
management of asthma. However, the 
long-term safety of regular treatment with 
formoterol at higher doses per day than 
those recommended by the manufacturer 
has not been established. Therefore, it 
is imperative to instruct the patient that 
formoterol should ONLY be used every 12 
hours.
Dose	comparison
In most adult patients treated with 
inhaled long-acting beta2-adrenoreceptor 
agonists, symptoms will be satisfactorily 
controlled on 0mcg salmeterol twice 
daily or 12mcg formoterol twice daily. 
If these drugs are used in higher doses, 
attention must be paid to side effects. 
Studies in adult patients with mild-to-
moderate asthma showed that salmeterol 
0mcg8, and formoterol, 12 and 24mcg9, 
administered from a metered-dose 
inhaler were safe and had a low degree 
of cardiac effects. However, studies10,11 
comparing the cardiovascular effects of 
formoterol and salmeterol administered 
at the recommended single doses in 
patients suffering from chronic obstructive 
pulmonary disease (COPD) with preexisting 
mild-to-moderate arrhythmias and 
hypoxaemia suggested that formoterol 
24mcg induces a statistically significant 
increase in heart rate when compared 
with placebo and formoterol 12mcg, and 
salmeterol 0mcg. Additionally both 
formoterol 12mcg and salmeterol 0mcg 
have a significantly greater effect than 
placebo, but there were no differences 
between these two treatments. 
Beta2-adrenoreceptor agonists can 
decrease plasma potassium levels by 
stimulation of beta2-adrenoreceptors in the 
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liver and skeletal muscle. With the 24mcg 
dose, but not the 12mcg dose, formoterol 
produces a statistically significant decrease 
in serum potassium levels in patients with 
mild-to-moderate asthma. Also, salmeterol 
in doses up to a 0mcg was not found to 
modify the serum potassium level, whereas 
there was a trend toward a decrease in 
potassium with a 100mcg dose in patients 
with mild-to-moderate asthma. 
Moreover, doses higher than 12mcg in 
the case of formoterol and 0mcg in the 
case of salmeterol do not improve FEV1 
further, thus not showing dose-dependent 
effects of the drugs on this measurement. 
Therefore, formoterol produces little 
additional effect in dosages beyond 12mcg 
twice daily. Salmeterol produces little 
additional effect in dosages beyond 0mcg 
twice daily but does produce more side 
effects. Therefore, the recommended single 
dose of salmeterol 0mcg and formoterol 
12mcg allows a relatively higher safety 
margin than salmeterol 100mcg and 
formoterol 24mcg.10 
Formoterol	and	salmeterol	
as	add-on	therapy	in	asthma	
Studies have shown that adding a 
long-acting beta2-adrenoreceptor agonist 
to patients who are not controlled with 
inhaled glucocorticoids only, statistically 
significantly decreases exacerbations 
and hospitalizations in these patients.1 
These studies have also shown that in 
patients with persistent asthma combining 
salmeterol or formoterol with a median of 
400mcg of beclomethasone or equivalent 
results in greater improvement from 
baseline in FEV1, in symptom-free days 
and in the daytime use of rescue beta2-
adrenoreceptor agonists than prescribing 
a higher dose of inhaled glucocorticoids 
only (median of 800 to 1000mcg per day of 
beclomethasone or equivalent).14 However, 
long acting inhaled beta2–adrenoreceptor 
agonists should only be prescribed as add 
on therapy in asthmatic patients who are 
already taking inhaled glucocorticoids.1 It 
is important that formoterol or salmeterol 
should not be used as monotherapy in 
asthma as these medications do not appear 
to influence the airway inflammation in 
asthma.16 Results from the Salmeterol-Multi 
Centre Asthma Research Trial (SMART) 
showed that patients who did not use 
inhaled glucocorticoids with salmeterol 
Salmeterol Formoterol
Onset	of	action 1-0 minutes 1- minutes
Duration Up to 12 hours Up to 12 hours
Efficacy Partial agonist Full agonist (higher efficacy)
Peak	bronchodilation 1-2 hours 0 minutes
Drop	in	serum	potassium Drop in serum K+ Possible larger drop in serum K+ 
Finger	tremor Pronounced More pronounced
Heart	rate	and	Q-Tc	intervals No significant difference 
compared to formoterol
No significant difference 
compared to salmeterol
Table	1.	Pharmacological	differences	between	formoterol	and	salmeterol2,4,5,6
had a higher incidence of asthma-related 
adverse events than patients who did use 
inhaled corticosteroids with salmeterol.1,1-19 
When administered as an aerosol by 
a metered-dose inhaler or when inhaled 
as a powder via a dry-powder inhaler, 
formoterol and salmeterol have the 
property of retaining a bronchodilatory 
effect for up to 12 hours, which accounts 
for their use in patients with nocturnal 
asthma. Moreover, the long duration of 
action permits for a twice daily treatment 
frequency, rather than every 4 hours as with 
short-acting beta2-ardrenoreceptor agonists 
thereby encouraging patient adherence to 
treatment.2 
1. Before prescribing add-on therapy, practitioners should assess adherence, inhaler 
technique and attempt to eliminate trigger factors. 
2. The first choice as add-on therapy to inhaled steroids in adults and children 
 (-12 years) is an inhaled long-acting beta2-adrenoreceptor agonist 
 (formoterol or salmeterol).
. If there is no response to treatment the drug should be discontinued.
Table	2.	Criteria	for	introduction	of	add-on	therapy15
Table	3.	Advantages	of	formoterol	and	salmeterol	as	add-on	therapy16
1. Improve symptom scores
2. Decrease nocturnal asthma 
. Improve lung function
4. Decrease the use of short-acting inhaled beta2-adrenoreceptor agonists
. Reduce the number of exacerbations
6. Achieve clinical control of asthma in more patients, more rapidly, 
 and at a lower dose of inhaled glucocorticosteroids than when 
 inhaled glucocorticosteroids are given alone. 
. May be used to prevent exercise-induced bronchospasm since they provide a longer 
 protection than rapid-acting inhaled beta2-adrenoreceptor agonists. 
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Advantages	of	long-acting	
beta2-adrenoreceptor	agonists
Addition of long-acting inhaled beta2-
adrenoreceptor agonists to a daily regimen 
of inhaled glucocorticoids in asthmatic 
patients has various advantages, as listed 
in Table .
Long-acting	beta2-adrenoreceptor	
agonists	in	COPD
In COPD, airflow is obstructed during 
expiration, thus causing dyspnoea. 
In contrast to asthma, the airflow 
obstruction is not reversible and usually 
progresses over time.20 The major goals 
of bronchodilator therapy in COPD are to 
prevent exacerbation, achieve symptom 
relief, improve pulmonary functions and, 
in the long term, enhance the quality of 
life.19 Results of systematic reviews or 
large randomized clinical trials indicate 
that long-acting beta2-adrenoreceptor 
agonists in patients suffering from COPD 
without asthma, statistically significantly 
reduce airflow obstruction and symptoms. 
However, the clinical significance is unclear 
and careful consideration of the costs and 
benefits of long-acting beta2-adrenoreceptor 
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•	 Patients with asthma given salmeterol or formoterol should always initially be 
prescribed an inhaled glucocorticoids.1
•	 Patients should be monitored closely during early treatment.1
•	 Long-acting beta2-adrenoreceptor agonists should ONLY be used every 12 hours.
•	 A dose of 0mcg salmeterol twice daily is comparable to 12mcg formoterol 
twice daily.
•	 Inhaler technique should always be reviewed prior to making any changes in 
the patient’s treatment.
•	 Different brands of long-acting inhaled beta2-adrenoreceptor agonists have 
different licensing properties. Some of these preparations are not licensed for 
certain age groups. It is imperative to always refer to specific manufacture 
recommendations prior to prescribing long-acting inhaled beta2-adrenoreceptor 
agonists.
Practice	Points
agonists in patients without asthma is 
needed before using these drugs in COPD.21 
Delivery	
Inhaled long-acting beta2-
adrenoreceptor agonists may be delivered 
via a metered dose inhaler or a dry 
powder inhaler. It is essential that health 
care professionals proactively engage in 
instructing patients on inhaler technique. 
An inhaler should only be prescribed after 
the patient has received the necessary 
training and has demonstrated his/her 
ability to use the device properly. Regular 
assessment of inhaler technique is 
imperative as inappropriate technique 
leads to inadequate delivery resulting in 
suboptimal control. Information regarding 
training of inhaler technique may be 
accessed at www.ginasthma.com.22
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